Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Stein

Showing results (131-140 of 143) with videos related to

Pageof 15
Sort By:
Cancer Immunology Research|November 11, 2024
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and ImmunotherapyJoseph Tintelnot, Lisa Paschold, Eray Goekkurt, et al.
Journal of Cancer Research and Clinical Oncology|October 1, 2024
Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123)David Witte, Ina Pretzell, Timm M Reissig, et al.
JAMA Oncology|June 23, 2022
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical TrialAlexander Stein, Lisa Paschold, Joseph Tintelnot, et al.
Journal for Immunotherapy of Cancer|July 28, 2021
PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancerAlexander Stein, Donjete Simnica, Christoph Schultheiß, et al.
Frontiers in Oncology|January 6, 2023
Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancerJoseph Tintelnot, Inka Ristow, Markus Sauer, et al.
Nature Medicine|April 14, 2023
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trialVivek Subbiah, Robert J Kreitman, Zev A Wainberg, et al.
The New England Journal of Medicine|June 2, 2025
Perioperative Durvalumab in Gastric and Gastroesophageal Junction CancerYelena Y Janjigian, Salah-Eddin Al-Batran, Zev A Wainberg, et al.
The Lancet. Oncology|November 28, 2021
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trialPatrick Y Wen, Alexander Stein, Martin van den Bent, et al.
Nature|May 13, 2025
Author Correction: Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancerJoseph Tintelnot, Yang Xu, Till R Lesker, et al.
JAMA Network Open|March 25, 2024
A Multimodal Lifestyle Psychosocial Survivorship Program in Young Cancer Survivors: The CARE for CAYA Program-A Randomized Clinical Trial Embedded in a Longitudinal Cohort StudyJulia von Grundherr, Simon Elmers, Barbara Koch, et al.
Pageof 15

Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
Cancer Immunology Research|November 11, 2024
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and ImmunotherapyJoseph Tintelnot, Lisa Paschold, Eray Goekkurt, et al.
Journal of Cancer Research and Clinical Oncology|October 1, 2024
Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123)David Witte, Ina Pretzell, Timm M Reissig, et al.
JAMA Oncology|June 23, 2022
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical TrialAlexander Stein, Lisa Paschold, Joseph Tintelnot, et al.
Journal for Immunotherapy of Cancer|July 28, 2021
PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancerAlexander Stein, Donjete Simnica, Christoph Schultheiß, et al.
Frontiers in Oncology|January 6, 2023
Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancerJoseph Tintelnot, Inka Ristow, Markus Sauer, et al.
Nature Medicine|April 14, 2023
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trialVivek Subbiah, Robert J Kreitman, Zev A Wainberg, et al.
The New England Journal of Medicine|June 2, 2025
Perioperative Durvalumab in Gastric and Gastroesophageal Junction CancerYelena Y Janjigian, Salah-Eddin Al-Batran, Zev A Wainberg, et al.
The Lancet. Oncology|November 28, 2021
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trialPatrick Y Wen, Alexander Stein, Martin van den Bent, et al.
Nature|May 13, 2025
Author Correction: Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancerJoseph Tintelnot, Yang Xu, Till R Lesker, et al.
JAMA Network Open|March 25, 2024
A Multimodal Lifestyle Psychosocial Survivorship Program in Young Cancer Survivors: The CARE for CAYA Program-A Randomized Clinical Trial Embedded in a Longitudinal Cohort StudyJulia von Grundherr, Simon Elmers, Barbara Koch, et al.
Pageof 15